Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma

Leukemia

Volumn 31, Issue 2, 2017, Pages 373-381

  McNee, G ^a   Eales, K L ^a   Wei, W ^a   Williams, D S ^a   Barkhuizen, A ^b   Bartlett, D B ^a   Essex, S ^a   Anandram, S ^b   Filer, A ^a   Moss, P A H ^a   Pratt, G ^a,c   Basu, S ^b   Davies, C C ^a   Tennant, D A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BORTEZOMIB; CARRIER PROTEINS AND BINDING PROTEINS; FILAGGRIN; HISTONE H3; INTERLEUKIN 6; MEMBRANE PROTEIN; MESSENGER RNA; PEPTIDYL ARGININE DEIMINASE 2; PROTEIN; PROTEIN ARGININE DEIMINASE; SLC14A1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HISTONE; TRANSCRIPTOME;

APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHEMICAL MODIFICATION; CITRULLINATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; BIOLOGICAL MODEL; CELL CULTURE; CLUSTER ANALYSIS; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELLS, CULTURED; CLUSTER ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; MODELS, BIOLOGICAL; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; TRANSCRIPTOME;

EID: 84981507121     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.187     Document Type: Article

References (47)

1. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
2. Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009; 94: 1708-1713.
3. Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology 2013; 2013: 478-487.
4. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860.
5. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007; 21: 1007-1034, vii-viii.
6. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006; 132: 385-397.
7. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
8. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007; 48: 2032-2041.
9. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001; 91: 1219-1230.
10. Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kandefer-Szerszen M. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 2008; 56: 207-221.
11. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 158-163.
12. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009; 23: 1515-1527.
13. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
14. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112.
15. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002; 1: 539-544.
16. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signalling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
17. Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N et al. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32.3) and FGFR3 translocation. Int J Oncol 1999; 15: 1205-1212.
18. Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 1999; 104: 350-357.
19. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003; 17: 764-774.
20. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002; 16: 1182-1188.
21. Dezorella N, Pevsner-Fischer M, Deutsch V, Kay S, Baron S, Stern R et al. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Exp Cell Res 2009; 315: 1904-1913.
22. Wang S, Wang Y. Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta 2013; 1829: 1126-1135.
23. Rus'd AA, Ikejiri Y, Ono H, Yonekawa T, Shiraiwa M, Kawada A et al. Molecular cloning of cDNAs of mouse peptidylarginine deiminase type I, type III and type IV, and the expression pattern of type I in mouse. Eur J Biochem 1999; 259: 660-669.
24. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003; 25: 1106-1118.
25. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56: 3541-3553.
26. van Beers JJ, Zendman AJ, Raijmakers R, Stammen-Vogelzangs J, Pruijn GJ. Peptidylarginine deiminase expression and activity in PAD2 knock-out and PAD4-low mice. Biochimie 2013; 95: 299-308.
27. Zhang X, Bolt M, Guertin MJ, Chen W, Zhang S, Cherrington BD et al. Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor alpha target gene activation. Proc Natl Acad Sci USA 2012; 109: 13331-13336.
28. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T, Yamada M et al. Histone deimination antagonizes arginine methylation. Cell 2004; 118: 545-553.
29. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004; 306: 279-283.
30. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004; 20: 3705-3706.
31. Koch CM, Andrews RM, Flicek P, Dillon SC, Karaoz U, Clelland GK et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 2007; 17: 691-707.
32. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008; 112: 196-207.
33. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibodybased inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106-2111.
34. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
35. Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, Allwood JW et al. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Blood Cancer J 2015; 5: e359.
36. Bergfeld SA, Blavier L, DeClerck YA. Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther 2014; 13: 962-975.
37. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004; 21: 399-408.
38. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580.
39. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS et al. Inhibition of interleukin-6 signalling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478.
40. Dreyton CJ, Knuckley B, Jones JE, Lewallen DM, Thompson PR. Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism. Biochemistry 2014; 53: 4426-4433.
41. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104: 439-444.
42. Kyle RA, Beard CM, O'Fallon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol 1994; 12: 1577-1583.
43. San-Miguel J, Blade J, Shpilberg O, Grosicki S, Maloisel F, Min CK et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136-4142.
44. McElwee JL, Mohanan S, Horibata S, Sams KL, Anguish LJ, McLean D et al. PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia. Cancer Res 2014; 74: 6306-6317.
45. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63: 373-381.
46. Ishigami A, Masutomi H, Handa S, Nakamura M, Nakaya S, Uchida Y et al. Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer's disease brains. J Neurosci Res 2015; 93: 1664-1674.
47. Carrillo-Vico A, Leech MD, Anderton SM. Contribution of myelin autoantigen citrullination to T cell autoaggression in the central nervous system. J Immunol 2010; 184: 2839-2846.